MX2020013896A - Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso. - Google Patents
Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso.Info
- Publication number
- MX2020013896A MX2020013896A MX2020013896A MX2020013896A MX2020013896A MX 2020013896 A MX2020013896 A MX 2020013896A MX 2020013896 A MX2020013896 A MX 2020013896A MX 2020013896 A MX2020013896 A MX 2020013896A MX 2020013896 A MX2020013896 A MX 2020013896A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrrolo
- intermediates
- manufacturing process
- pyrimidine compound
- crystalline form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862694698P | 2018-07-06 | 2018-07-06 | |
| US201862776642P | 2018-12-07 | 2018-12-07 | |
| US201962855071P | 2019-05-31 | 2019-05-31 | |
| PCT/IB2019/055683 WO2020008391A1 (en) | 2018-07-06 | 2019-07-03 | Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013896A true MX2020013896A (es) | 2021-03-09 |
Family
ID=67928862
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013896A MX2020013896A (es) | 2018-07-06 | 2019-07-03 | Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso. |
| MX2023006842A MX2023006842A (es) | 2018-07-06 | 2020-12-16 | Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006842A MX2023006842A (es) | 2018-07-06 | 2020-12-16 | Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10815240B2 (enExample) |
| EP (1) | EP3817810B1 (enExample) |
| JP (1) | JP7437646B2 (enExample) |
| KR (1) | KR102568464B1 (enExample) |
| CN (1) | CN112384282B (enExample) |
| AU (1) | AU2019299666B2 (enExample) |
| BR (1) | BR112020025701A2 (enExample) |
| CA (1) | CA3105161C (enExample) |
| ES (1) | ES3045115T3 (enExample) |
| IL (1) | IL279926B2 (enExample) |
| MX (2) | MX2020013896A (enExample) |
| TW (1) | TWI709562B (enExample) |
| WO (1) | WO2020008391A1 (enExample) |
| ZA (1) | ZA202100196B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020232470A1 (en) | 2019-05-13 | 2020-11-19 | Boragen, Inc. | Chemical compounds |
| CN113637018A (zh) | 2020-04-27 | 2021-11-12 | 苏州晶云药物科技股份有限公司 | 磺酰胺类化合物的晶型及其制备方法 |
| CN112279785B (zh) * | 2020-10-29 | 2022-08-16 | 苏利制药科技江阴有限公司 | 3,3-二氟环丁胺盐酸盐中间体及其合成方法和3,3-二氟环丁胺盐酸盐合成方法 |
| CN113583992B (zh) * | 2021-07-15 | 2023-06-27 | 华东理工大学 | 一种还原胺化酶及其在仲胺合成中的应用 |
| US20240383893A1 (en) * | 2021-09-10 | 2024-11-21 | Haihe Biopharma Co., Ltd. | Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof |
| ES2993658B2 (es) | 2023-06-27 | 2025-07-02 | Moehs Iberica Sl | (3-(metil(7h-pirrolo[2,3-d]pirimidin-4-il)amino)ciclobutilo)carbamato de bencilo o una sal del mismo, procedimiento para su preparacion y su uso en la sintesis de abrocitinib |
| ES3040374A1 (es) | 2024-04-30 | 2025-10-30 | Moehs Iberica Sl | Cocristales de N-{cis-3-[metil(7H-pirrolo[2,3-d]pirimidin-4-il)amino]ciclobutil}propano-1-sulfonamida |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| JP4126781B2 (ja) | 1998-10-26 | 2008-07-30 | 宇部興産株式会社 | １−スルホニルピラゾール誘導体及びその製造方法 |
| JP2003005323A (ja) | 2001-06-20 | 2003-01-08 | Konica Corp | 熱現像写真感光材料及び画像形成方法 |
| GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| CN102471248B (zh) * | 2009-08-10 | 2015-01-07 | Bhi有限合伙公司 | 用于递送1,3-丙二磺酸的方法、化合物和组合物 |
| BR112014000315A2 (pt) | 2011-07-08 | 2016-08-23 | Syngenta Participations Ag | processos para a preparação de tietanamina |
| EP3290421B1 (en) * | 2013-02-22 | 2019-01-02 | Pfizer Inc | Combination of pyrrolo [2, 3 -d]pyrimidine derivatives with one or more additional agents as inhibitors of janus- related kinases (jak) |
| JP6585158B2 (ja) | 2014-08-12 | 2019-10-02 | ファイザー・インク | ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体 |
-
2019
- 2019-07-03 IL IL279926A patent/IL279926B2/en unknown
- 2019-07-03 TW TW108123441A patent/TWI709562B/zh active
- 2019-07-03 EP EP19766356.0A patent/EP3817810B1/en active Active
- 2019-07-03 CN CN201980045496.5A patent/CN112384282B/zh active Active
- 2019-07-03 CA CA3105161A patent/CA3105161C/en active Active
- 2019-07-03 BR BR112020025701-0A patent/BR112020025701A2/pt unknown
- 2019-07-03 AU AU2019299666A patent/AU2019299666B2/en active Active
- 2019-07-03 WO PCT/IB2019/055683 patent/WO2020008391A1/en not_active Ceased
- 2019-07-03 MX MX2020013896A patent/MX2020013896A/es unknown
- 2019-07-03 US US16/502,703 patent/US10815240B2/en active Active
- 2019-07-03 KR KR1020217003518A patent/KR102568464B1/ko active Active
- 2019-07-03 ES ES19766356T patent/ES3045115T3/es active Active
- 2019-07-04 JP JP2019124976A patent/JP7437646B2/ja active Active
-
2020
- 2020-09-29 US US17/036,849 patent/US11254684B2/en active Active
- 2020-12-16 MX MX2023006842A patent/MX2023006842A/es unknown
-
2021
- 2021-01-12 ZA ZA2021/00196A patent/ZA202100196B/en unknown
-
2022
- 2022-01-10 US US17/572,089 patent/US12018031B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023006842A (es) | 2023-06-22 |
| US20220127274A1 (en) | 2022-04-28 |
| IL279926A (en) | 2021-03-01 |
| TW202017929A (zh) | 2020-05-16 |
| TWI709562B (zh) | 2020-11-11 |
| CN112384282A (zh) | 2021-02-19 |
| EP3817810A1 (en) | 2021-05-12 |
| JP7437646B2 (ja) | 2024-02-26 |
| WO2020008391A1 (en) | 2020-01-09 |
| CN112384282B (zh) | 2024-07-02 |
| US10815240B2 (en) | 2020-10-27 |
| CA3105161A1 (en) | 2020-01-09 |
| US20210009601A1 (en) | 2021-01-14 |
| JP2020007308A (ja) | 2020-01-16 |
| IL279926B1 (en) | 2023-08-01 |
| AU2019299666A1 (en) | 2021-01-07 |
| US11254684B2 (en) | 2022-02-22 |
| US20200123159A1 (en) | 2020-04-23 |
| ES3045115T3 (en) | 2025-11-27 |
| EP3817810B1 (en) | 2025-09-17 |
| AU2019299666B2 (en) | 2024-07-11 |
| US12018031B2 (en) | 2024-06-25 |
| ZA202100196B (en) | 2022-09-28 |
| CA3105161C (en) | 2022-11-15 |
| IL279926B2 (en) | 2023-12-01 |
| BR112020025701A2 (pt) | 2021-03-16 |
| KR102568464B1 (ko) | 2023-08-21 |
| EP3817810C0 (en) | 2025-09-17 |
| KR20210029234A (ko) | 2021-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013896A (es) | Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso. | |
| MX387902B (es) | PROCESO PARA LA PREPARACION DE PIRAZOLO[1,5-a]PIRIMIDINAS Y SALES DE ESTAS. | |
| EP4467549A3 (en) | Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives | |
| PH12018500437A1 (en) | Novel pyrazolo [3,4-d] pyrimidine compounds or salt thereof | |
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| MX2021003241A (es) | Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo. | |
| ECSP088350A (es) | Pirazolopirimidinas como inhibidores de protein quinasas | |
| ECSP066718A (es) | Derivados de pirazolo[1,5-a]pirimidin-7-il-amina para usar en el tratamiento de enfermedades dependientes de la proteina quinasa | |
| GEP20217242B (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| EA202091016A1 (ru) | Пиримидиновое соединение в качестве ингибитора jak киназы | |
| PH12020550143A1 (en) | Salts of pyrrolotriazine derivatives useful as tam inhibitors | |
| EA201290147A1 (ru) | Пирроло[2,3-d]пиримидиновые соединения | |
| MX2016007371A (es) | Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados. | |
| EA201000090A1 (ru) | Тризамещенные производные пиримидина для лечения пролиферативных заболеваний | |
| SG10201902206QA (en) | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof | |
| SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 | |
| PH12021552533A1 (en) | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease | |
| EA202090385A1 (ru) | Новые промежуточные соединения, используемые для синтеза производных аминопиримидина, способ их получения и способ получения производных аминопиримидина с их использованием | |
| MX394882B (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta) | |
| MX2021002042A (es) | Inhibidores de arginasa y sus metodos de uso. | |
| MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
| MX2021009796A (es) | Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5). | |
| BR112019008163A2 (pt) | compostos de [1,2,4]triazolo[1,5-a]pirimidina como inibidores de pde2 | |
| CL2018002344A1 (es) | Proceso para preparar compuestos de 7h-pirrolo[2,3-d]pirimidina | |
| MX381037B (es) | Formas cristalinas y formas de sal de compuestos de 7h-pirrolo [2,3-d]pirimidina y método de preparación de las mismas. |